
India

ADD (no change)

Consensus ratings*: Buy 7	Hold 7 Sell 13
Current price:	Rs4,991
Target price:	Rs5,649
Previous target:	Rs4,707
Up/downside:	13.2%
InCred Research / Consensus:	45.7%
Reuters:	
Bloomberg:	DIVI IN
Market cap:	US\$15,822m
	Rs1,325,020m
Average daily turnover:	US\$32.3m
	Rs2705.5m
Current shares o/s:	265.5m
Free float:	48.1%
*Source: Bloomberg	

Key changes in this note

Raise the target price to Rs5,649 (Rs4,707 earlier).



Relative (76)	0.5	13.2	0.2
Major shareholders		%	6 held
Promoters			51.9
SBI MF			8.3
LIC			6.0

Research Analyst(s)



Praful BOHRA T (91) 22 4161 1552 E praful.bohra@incredresearch.com Yogesh SONI T (91) 8850099267 E yogesh.soni@incredresearch.com

Divi's Laboratories

Visibility improving in CS business

- 1Q was broadly in line. The CS business continues to march ahead strongly with a 46% YoY growth while the generics business (flat YoY) is yet to rebound.
- Tailwinds from the Biosecure Act, large ongoing as well as completed capex and newer growth avenues like GLP-1 & contrast media keeps us constructive.
- No change in our earnings estimates. We retain ADD rating on the stock with a higher target price of Rs5,649 (from Rs4,707 earlier).

1QFY25 performance largely in line with expectations

Divi's Laboratories' 1QFY25 revenue/EBITDA broadly in line with our/consensus estimates, led by robust performance in the custom synthesis or CS business (+46% YoY). Generics and neutraceutical businesses were flat YoY. The EBITDA margin stood at 29.4%, 70bp above our estimate, led by better operating leverage. Gross margin declined by 110bp QoQ. In constant currency or CC terms, revenue was up 18% YoY, largely driven by volume. Generic pricing continues to remain weak amid inventory destocking at customers' end, but Divi's Laboratories witnessed a 2-5% growth in its large molecules, led by better volume. The company alluded to double-digit revenue growth in FY25F.

Higher enquiries; ongoing capex point to strong years going ahead

With the ongoing speculation around the Biosecure Act - which discourages US companies from working with Chinese biotech service providers – as well as deferred projects since the Covid-19 pandemic which are now getting fast-tracked, there has been a substantial rise in enquiries in the custom synthesis or CS business. This can throw up positive surprises, and lead to better-than-expected growth visibility in the CS business, thereby driving better margins. Further, on the peptides, Divi's Laboratories is now transitioning to producing fragments (from only building blocks earlier), which raises the value proposition for clients. It is currently working with a 50-L reactor on pilot basis but has already ordered two 500L reactors for commercial manufacture of fragments (both in solid & liquid states).

Capex update

a) The first phase of the Kakinada plant will get commercialized by 2HFY25F; the company has spent around Rs10.2bn so far on the Kakinada plant. b) Maintenance capex will be Rs2.5bn for FY25F. c) Current plant utilization is 82%. d) Current asset turn is in the range of 0.6-0.7x and after completion of the capex cycle, it is expected to touch 1x.

Retain ADD rating with a higher target price of Rs5,649

There is no change in our earnings estimates. We retain ADD rating on the stock with a higher target price of Rs5,649 (Rs4,707 earlier). The higher multiple is to account for potential optionality in the CS business, given Divi's Laboratories is capex-ready with huge expansion in the last four-to-five years. Any slowdown in the CS business is a key downside risk.

Financial Summary	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue (Rsm)	89,598	77,675	78,450	87,841	101,972
Operating EBITDA (Rsm)	38,819	23,669	22,030	27,179	34,504
Net Profit (Rsm)	29,605	18,225	16,000	19,646	24,993
Core EPS (Rs)	111.5	68.7	60.3	74.0	94.1
Core EPS Growth	49.2%	(38.4%)	(12.2%)	22.8%	27.2%
FD Core P/E (x)	44.76	72.70	82.81	67.44	53.02
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
EV/EBITDA (x)	33.39	54.17	58.30	47.19	36.91
P/FCFE (x)	42.60	29.80	87.23	48.29	46.39
Net Gearing	(24.0%)	(33.0%)	(29.3%)	(28.3%)	(30.3%)
P/BV (x)	11.30	10.38	9.76	8.99	7.93
ROE	28.2%	14.9%	12.1%	13.9%	15.9%
% Change In Core EPS Estimates					
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

InCred Equities

Pharmaceuticals | India Divi's Laboratories | August 04, 2024

(Rs m)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	Y-o-Y (%)	Q-o-Q (%)
Revenue	22,545	18,545	17,077	19,508	17,780	19,090	18,550	23,030	21,180	19%	-8%
Consumption of raw materials	8,120	6,746	7,396	8,276	6,880	8,100	7,290	9,020	8,530	24%	-5%
as % of sales	36.0%	36.4%	43.3%	42.4%	38.7%	42.4%	39.3%	39.2%	40.3%		
Employee costs	2,464	2,321	2,389	2,576	2,630	2,660	2,680	2,970	2,920	11%	-2%
as % of sales	10.9%	12.5%	14.0%	13.2%	14.8%	13.9%	14.4%	12.9%	13.8%		
Other expenditure	3495	3268	3210	3780	3230	3540	3690	3730	3510	9%	-6%
as % of sales	15.5%	17.6%	18.8%	19.4%	18.2%	18.5%	19.9%	16.2%	16.6%		
EBITDA	8,467	6,210	4,083	4,876	5,040	4,790	4,890	7,310	6,220	23%	-15%
Margins (%)	37.6%	33.5%	23.9%	25.0%	28.3%	25.1%	26.4%	31.7%	29.4%		
Depreciation	837	857	868	870	930	950	950	950	970		
Other Income	884	801	1,143	662	810	860	950	790	790		
Interest	1	2	1	2	0	10	0	20	0		
PBT	8,513	6,152	4,356	4,665	4,920	4,690	4,890	7,130	6,040	23%	-15%
Total Tax	1,493	1,216	1,288	1,455	1,360	1,210	1,310	1,750	1,740		
Tax Rate (%)	17.5%	19.8%	29.6%	31.2%	27.6%	25.8%	26.8%	24.5%	28.8%		
PAT before MI	7,020	4,936	3,068	3,210	3,560	3,480	3,580	5,380	4,300	21%	-20%
Minority interest (MI)	0	0	0	0	0	0	0	0	0		
Adj. PAT before extraordinary items	7,020	4,936	3,068	3,210	3,560	3,480	3,580	5,380	4,300	21%	-20%
Extraordinary expenses	0	0	0	0	0	0	0	0	0		
Reported PAT	7,020	4,936	3,068	3,210	3,560	3,480	3,580	5,380	4,300	21%	-20%
No. of shares	265.4	265.5	265.5	265.5	265.5	265.5	265.5	265.5	265.5		
EPS	26.5	18.6	11.6	12.1	13.4	13.1	13.5	20.3	16.2		

Figure 2: Margin profile											
Margins (%)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	Y-o-Y (bp)	Q-o-Q (bp)
Gross	64%	64%	57%	58%	61%	58%	61%	61%	60%	-158	-111
EBITDA	38%	33%	24%	25%	28%	25%	26%	32%	29%	102	-237
Adj.PAT	31%	27%	18%	16%	20%	18%	19%	23%	20%	28	-306
Effective tax rate	18%	20%	30%	31%	28%	26%	27%	25%	29%	117	426
								SOURCE: INCF	RED RESEAR	CH, COMPAN	IY REPORTS

(Rs m)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	Y-o-Y (%) C	≀-o-Q (%)
Generic business	8,736	8,941	8,746	10,010	8,888	9,404	8,487	9,405	9,022	2%	-4%
% total revenue	38.7%	48.2%	51.2%	51.3%	50.0%	49.3%	45.8%	40.8%	42.6%		
Custom synthesis	11,949	7,975	6,831	7,998	7,112	7,636	8,533	11,745	10,378	46%	-12%
% total revenue	53.0%	43.0%	40.0%	41.0%	40.0%	40.0%	46.0%	51.0%	49.0%		
Neutraceuticals	1,860	1,630	1,500	1,500	1,780	2,050	1,530	1,880	1,780	0%	-5%
% total revenue	8.3%	8.8%	8.8%	7.7%	10.0%	10.7%	8.2%	8.2%	8.4%		
Total revenue	22,545	18,545	17,077	19,508	17,780	19,090	18,550	23,030	21,180	19%	-8%


Figure 4: Actuals versus estimates					
	Actuals	Incred Est.	Variance (%)	Bloomberg Est.	Variance (%)
Revenue (Rsm)	21,180	20,447	3.6%	20,898	1.3%
EBITDA (Rsm)	6,220	5,875	5.9%	6,265	-0.7%
Margin (%)	29.4	28.7		30.0	
PAT (Rsm)	4,300	4,292	0.2%	4550	-5.5%
			SOUR	CE: INCRED RESEARCH, C	COMPANY REPORTS

Figure 5: Changes in our earnings e	stimates					
		FY25F			FY26F	
Change in earnings estimates	Old	New	Variance (%)	Old	New	Variance (%)
Revenue (Rsm)	87,841	87,841	-	1,01,972	1,01,972	-
EBITDA (Rsm)	27,179	27,179	-	34,504	34,504	-
Margin (%)	31	30.9		34	33.8	
PAT (Rsm)	19,646	19,646	-	24,993	24,993	-
				SOURCE: INCR	ED RESEARCH, CO	MPANY REPORTS

InCred Equities

Pharmaceuticals | India Divi's Laboratories | August 04, 2024

BY THE NUMBERS



Profit & Loss					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Net Revenues	89,598	77,675	78,450	87,841	101,972
Gross Profit	59,927	47,138	47,160	54,461	64,242
Operating EBITDA	38,819	23,669	22,030	27,179	34,504
Depreciation And Amortisation	(3,115)	(3,432)	(3,780)	(4,300)	(4,700)
Operating EBIT	35,704	20,237	18,250	22,879	29,804
Financial Income/(Expense)	(8)	(7)	(30)	(30)	(30)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	1,139	3,447	3,410	3,700	4,000
Profit Before Tax (pre-El)	36,835	23,677	21,630	26,549	33,774
Exceptional Items					
Pre-tax Profit	36,835	23,677	21,630	26,549	33,774
Taxation	(7,231)	(5,453)	(5,630)	(6,903)	(8,781)
Exceptional Income - post-tax					
Profit After Tax	29,605	18,225	16,000	19,646	24,993
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	29,605	18,225	16,000	19,646	24,993
Recurring Net Profit	29,605	18,225	16,000	19,646	24,993
Fully Diluted Recurring Net Profit	29,605	18,225	16,000	19,646	24,993

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
EBITDA	38,819	23,669	22,030	27,179	34,504
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(13,705)	4,188	(6,070)	943	(7,440)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(5,997)	(3,260)	(3,350)	(6,903)	(8,781)
Net Interest (Paid)/Received	(8)	(7)	(30)	(30)	(30)
Tax Paid	(7,128)	(6,709)	(6,730)	(10,573)	(12,751)
Cashflow From Operations	19,118	24,597	12,610	21,220	18,283
Capex	(7,130)	(4,730)	(10,030)	(15,000)	(8,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow					
Cash Flow From Investing	11,988	19,867	2,580	6,220	10,283
Debt Raised/(repaid)					
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(5,309)	(7,964)	(7,960)	(7,964)	(5,309)
Preferred Dividends					
Other Financing Cashflow	(50)	2,039	3,049	3,817	3,990
Cash Flow From Financing	(5,360)	(5,925)	(4,911)	(4,147)	(1,320)
Total Cash Generated	6,629	13,942	(2,331)	2,073	8,963
Free Cashflow To Equity	31,106	44,465	15,190	27,439	28,565
Free Cashflow To Firm	31,114	44,471	15,220	27,469	28,595

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Pharmaceuticals | India Divi's Laboratories | August 04, 2024

BY THE NUMBERS...cont'd

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Cash And Equivalents	28,189	42,131	39,800	41,873	50,836
Total Debtors	24,239	17,925	21,560	21,082	24,473
Inventories	28,286	30,004	31,840	29,866	34,670
Total Other Current Assets	2,801	3,057	3,550	3,514	4,079
Total Current Assets	83,515	93,117	96,750	96,334	114,058
Fixed Assets	47,875	49,292	55,130	65,830	69,130
Total Investments	720	771	820	820	820
Intangible Assets	75	53	40	40	40
Total Other Non-Current Assets	1,562	1,155	1,960	1,960	1,960
Total Non-current Assets	50,232	51,270	57,950	68,650	71,950
Short-term Debt	8				
Current Portion of Long-Term Debt					
Total Creditors	7,957	7,625	8,240	7,815	8,734
Other Current Liabilities	3,990	3,386	4,540	3,419	3,821
Total Current Liabilities	11,956	11,011	12,780	11,235	12,555
Total Long-term Debt	29			147	167
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	4,481	5,706	6,210	6,210	6,210
Total Non-current Liabilities	4,510	5,706	6,210	6,357	6,377
Total Provisions					
Total Liabilities	16,465	16,717	18,990	17,592	18,932
Shareholders Equity	117,282	127,671	135,710	147,392	167,076
Minority Interests					
Total Equity	117,282	127,671	135,710	147,392	167,076
Key Ratios					
Ney Natios		N		N. 055	
Revenue Growth	Mar-22A 28.6%	Mar-23A	Mar-24A 1.0%	Mar-25F 12.0%	Mar-26F 16.1%
	35.7%	(13.3%)		23.4%	27.0%
Operating EBITDA Growth	43.3%	(39.0%) 30.5%	(6.9%)	30.9%	33.8%
Operating EBITDA Margin Net Cash Per Share (Rs)		158.70	149.92	157.18	190.87
BVPS (Rs)	106.05 441.79	480.93	511.21	555.22	629.36
Gross Interest Cover			-		
Effective Tax Rate	4,463.04	3,020.51	608.33 26.0%	762.63	993.48
	19.0%	23.0%	20.0%	20.0%	20.0%
Net Dividend Payout Ratio	00.50	00.07	04.90	00.50	04.52
Accounts Receivables Days	83.52	99.07	91.86	88.59	81.53
Inventory Days	305.93	348.36	360.71	337.37	312.17
Accounts Payables Days	95.88	93.12	92.53	87.78	80.05
ROIC (%)	28.8%	16.7%	13.5%	15.4%	18.3%
ROCE (%) Return On Average Assets	34.0%	16.5%	13.9%	16.2%	18.9%
Roturn ()n Avorago Accote	24.5%	13.1%	10.7%	12.3%	14.3%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Pharmaceuticals | India Divi's Laboratories | August 04, 2024

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.